Login
Subscribe
oligonucleotides
Analyzing Oligonucleotide Purity with Capillary Electrophoresis
Agilent | Nov 7, 2022 | 1 min read
Identify small impurities introduced by oligonucleotide synthesis prior to experimentation.
Bacterial Metabolite May Regulate Cognition in Mice
Sophie Fessl, PhD | Jun 3, 2022 | 3 min read
Microbes in the gut influence the death of support cells in the brain by producing isoamylamine, a study suggests.
Customized Commercial Molecular Assay Development
Thermo Fisher Scientific | Mar 23, 2022 | 1 min read
Explore the latest in nucleic acid amplification.
Accelerating Drug Discovery: Focus on Nucleic Acid Therapeutics
Thermo Fisher Scientific | Sep 2, 2021 | 1 min read
Researchers develop strategies to prevent and treat diseases with nucleic acid therapies.
Antisense Oligonucleotides Cross Rodents’ Blood-Brain Barrier
Abby Olena, PhD | Aug 18, 2021 | 3 min read
RNA-DNA complexes that were modified with cholesterol made it into the brains of rats and mice, where they knocked down target genes.
Technique Talk: Troubleshooting Quantitative PCR (qPCR)
The Scientist’s Creative Services Team | Jan 18, 2021 | 5 min read
In this workshop, you will learn about the critical factors that ensure qPCR accuracy and success.
Understanding and Optimizing PCR
The Scientist’s Creative Services Team | Sep 25, 2020 | 1 min read
Do you know how to get the most out of your PCR reactions?
Breakthrough Prizes Recognize Aneuploidy Researcher, Biochemist
Catherine Offord | Oct 18, 2018 | 2 min read
This year’s winners also include the developers of nusinersen, an oligonucleotide therapeutic for spinal muscular atrophy.
Custom-Made Molecules
Ruth Williams | Aug 20, 2017 | 3 min read
A new prototype machine can make the biological molecules of one’s choice from digital DNA sequences.
FDA Approves First Treatment for Spinal Muscular Atrophy
Ben Andrew Henry | Dec 27, 2016 | 1 min read
The oligonucleotide therapeutic will soon be available in the U.S.
Oligonucleotide Therapeutics Near Approval
Catherine Offord | Dec 1, 2016 | 8 min read
Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.
Speaking of Neuroscience
Jef Akst and Mary Beth Aberlin | Nov 18, 2016 | 2 min read
A selection of notable quotes from the annual Society for Neuroscience meeting